Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 497 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others

REVIEW ARTICLE

Sodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: Wisdom of hindsight

Singh Awadhesh Kumar

Year : 2015| Volume: 19| Issue : 6 | Page no: 722-730

   This article has been cited by
 
1 Sodium-glucose co-transporter type-2 inhibitors: pharmacology and peri-operative considerations
D. A. Milder,T. Y. Milder,P. C. A. Kam
Anaesthesia. 2018;
[Pubmed]  [Google Scholar] [DOI]
2 SGLT2 Inhibitors and Ketoacidosis: Pathophysiology and Management
Yun Hyi Ku
The Korean Journal of Medicine. 2017; 92(5): 443
[Pubmed]  [Google Scholar] [DOI]
3 Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature
Benedetta Maria Bonora,Angelo Avogaro,Gian Paolo Fadini
Diabetes, Obesity and Metabolism. 2017;
[Pubmed]  [Google Scholar] [DOI]
4 Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists
Awadhesh Kumar Singh,Ritu Singh
Expert Review of Clinical Pharmacology. 2017; : 1
[Pubmed]  [Google Scholar] [DOI]
5 Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective
Tushar Madaan,Mohd. Akhtar,Abul Kalam Najmi
European Journal of Pharmaceutical Sciences. 2016;
[Pubmed]  [Google Scholar] [DOI]
6 Diabetic ketoacidosis, sodium glucose transporter-2 inhibitors and the kidney
Biff F. Palmer,Deborah J. Clegg,Simeon I. Taylor,Matthew R. Weir
Journal of Diabetes and its Complications. 2016;
[Pubmed]  [Google Scholar] [DOI]
7 Combination therapy of sodium–glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences
Awadhesh Kumar Singh,Ritu Singh
Expert Review of Clinical Pharmacology. 2016; 9(2): 229
[Pubmed]  [Google Scholar] [DOI]
8 SGLT2 Inhibitor–associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis
Ronald M. Goldenberg,Lori D. Berard,Alice Y.Y. Cheng,Jeremy D. Gilbert,Subodh Verma,Vincent C. Woo,Jean-François Yale
Clinical Therapeutics. 2016; 38(12): 2654
[Pubmed]  [Google Scholar] [DOI]
9 Euglycemic diabetic ketoacidosis in type 2 diabetes with sodium glucose cotransporter 2 inhibitors
An-Yi Wang,Sen-Kuang Hou,Shan-Jen Li,Wei-Fong Kao
The American Journal of Emergency Medicine. 2016;
[Pubmed]  [Google Scholar] [DOI]
10 Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes
Kalliopi Pafili,Efstratios Maltezos,Nikolaos Papanas
Expert Opinion on Drug Metabolism & Toxicology. 2016; : 1
[Pubmed]  [Google Scholar] [DOI]
11 Cardiac arrest from acute myocardial infarction complicated with sodium-glucose cotransporter 2 inhibitor-associated ketoacidosis
Zhehao Dai,Yosuke Nishihata,Naoto Kawamatsu,Ikki Komatsu,Atsushi Mizuno,Masato Shimizu,Nozomi Toya,Shinichi Ishimatsu,Nobuyuki Komiyama
Journal of Cardiology Cases. 2016;
[Pubmed]  [Google Scholar] [DOI]
12 Perfil clínico de los pacientes con diabetes mellitus tipo 2 tratados con inhibidores del cotransportador sodio-glucosa tipo 2 y experiencia clínica real en España
Gabriel Cuatrecasas,Fernando Goñi-Goicoechea
Medicina Clínica. 2016; 147: 30
[Pubmed]  [Google Scholar] [DOI]

 

Read this article